ClinicalTrials.gg
CompletedNCT01853046Updated Feb 20, 2017Results posted

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

A Phase 1 interventional study of Regorafenib (Stivarga, BAY73-4506) in Neoplasms, sponsored by Bayer. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-20.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with severe renal impairment when compared to the Control group (cancer subjects with normal or mildly impaired renal function)

02

Conditions studied

  • Neoplasms

Keywords

  • Regorafenib
  • pharmacokinetics
  • safety
  • severe renal impairment
  • Solid tumors
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 24 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with confirmed, locally advanced or , solid tumors who are not candidates for standard therapy
  • Male or female subject ≥ 18 years of age
  • Women of must have a negative urine pregnancy test performed within 7 days before start of study treatment
  • at least 8 weeks
  • Adequate bone marrow, and liver function as assessed by the following laboratory requirements conducted within 7 days of starting the study treatment
  • (ECOG) Performance Status of 0, 1 or 2
  • For subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be tested within 7 days of starting the study treatment:

    • Estimated (CLcr) ≥ 60 mL/min as calculated using the Cockcroft-Gault equation
  • For subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of starting the study treatment:

    • CLcr 15-29 mL/min as calculated using the Cockcroft-Gault equation

Exclusion criteria

Exclusion Criteria:

  • Symptomatic brain or meningeal tumors
  • Major surgical procedure, open , or significant traumatic injury within 28 days before start of study medication
  • History of organ allograft
  • Non-healing wound, skin ulcer, or bone fracture
  • Pheochromocytoma
  • Uncontrolled concurrent medical illness including uncontrolled hypertension
  • History of cardiac disease
  • Pleural effusion or ascites that causes respiratory compromise
  • Interstitial lung disease with ongoing signs and symptoms at the time of screening
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication
  • Subjects with evidence or history of bleeding diathesis; any hemorrhage or bleeding event Grade ≥ 3 or higher within 4 weeks of start of treatment
  • Dehydration NCI-CTCAEversion 4.0 Grade ≥ 1
  • Unresolved toxicity higher than NCI-CTCAE version 4.0 Grade 1 attributed to any prior therapy/procedure (excluding alopecia or anemia or grade 2 neuropathy that is not reversible due to oxaliplatin)
  • Seizure disorder requiring anticonvulsant therapy (such as or anti-epileptics)
  • For subjects with SEVERELY IMPAIRED renal function:

    • Renal failure requiring hemo- or peritoneal dialysis
    • Acute renal failure
    • Acute nephritis
    • Nephrotic syndrome
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment

    Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.

    Drug: Regorafenib (Stivarga, BAY73-4506)

  • Experimental
    Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment

    Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.

    Drug: Regorafenib (Stivarga, BAY73-4506)

Interventions

  • Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)

06

What researchers measure

Primary outcomes

  1. AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation. The AUC(0-tlast) \[Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point \>LLOQ (Lower Limit of Quantification)\] is a measure of systemic drug exposure from time 0 up to the time point at which the last measurable drug could be detectable, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  2. AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8

    Amount of drug excreted into urine during the collection interval 0-24 hours post dose was expressed as percentage of administered dose.

    Time frame: Days 1-2: 0-24 hours

Secondary outcomes

  1. AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation. AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  2. AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation. The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUC(0-24) is defined as AUC divided from zero to 24 hours after single (first) dose.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10 and 24 hours post-dose

  3. Cmax (Maximum Drug Concentration in Plasma After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  4. Tmax (Time to Reach Maximum Drug Concentration in Plasma After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation.Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  5. Tlast (Time of Last Data Point >LLOQ) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    based on non-compartmental PK evaluation.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  6. t1/2 (Half-life Associated With the Terminal Slope) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation. t1/2 refers to the elimination of the drug. It is the time taken for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. It is expressed in hours (h) and derived from the terminal slope of the concentration versus time curve.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  7. CL/F (Total Body Clearance of Drug After Extravascular Administration) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation.Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  8. Vz/F (Apparent Volume of Distribution During Terminal Phase After Single (First) Oral Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation.Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  9. AUC(0-24)md ((AUC(0-24) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation.

    Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10 and 24 hours post-dose

  10. Cmax,md (Cmax After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

    Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  11. AUC(0-tlast)md (AUC(0-tlast) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    based on non-compartmental PK evaluation.

    Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  12. Tmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    based on non-compartmental PK evaluation

    Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  13. Tlast,md (Tlast After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    based on non-compartmental PK evaluation

    Time frame: Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose

  14. RACmax (Accumulation Ratio Calculated From Cmax,md and Cmax) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation. Accumulation ratio based on maximum plasma concentration (Cmax) was calculated as ratio of Cmax,md and Cmax.

    Time frame: Up to 25 days

  15. RAAUC (Accumulation Ratio Calculated From AUC(0-24)md and AUC(0-24)) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation. RAAUC calculated as ratio of AUC(0-24)md and AUC(0-24).

    Time frame: Up to 25 days

  16. RLin (Linearity Factor Calculated as Ratio From AUC(0-24)md and AUC) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

    Based on non-compartmental PK evaluation. RLin is the linearity factor of PK after multiple administrations of identical doses calculated as ratio of AUC(0-24)md and AUC.

    Time frame: Up to 25 days

  17. AE,ur(0-24)md (AE,ur(0-24) After Multiple-dose Administration) for Metabolites M-7 and M-8

    based on non-compartmental PK evaluation

    Time frame: Days 21-22: 0-24 hours

  18. AE,ur(0-10) Stage 1 (Amount of Drug Excreted Via Urine During the Collection Interval 0-10 Hours Post Administration) for Metabolites M-7 and M-8

    based on non-compartmental PK evaluation

    Time frame: Days 1-2: 0-10 hours

  19. AE,ur(10-24) Stage 1 ((Amount of Drug Excreted Via Urine During the Collection Interval 10-24 Hours Post Administration) for Metabolites M-7 and M-8

    based on non-compartmental PK evaluation

    Time frame: Days 1-2: 10-24 hours

  20. AE,ur(0-10) Stage 2 for Metabolites M-7 and M-8

    based on non-compartmental PK evaluation

    Time frame: Days 21-22: 0-10 hours

  21. AE,ur(10-24) Stage 2 for Metabolites M-7 and M-8

    based on non-compartmental PK evaluation

    Time frame: Days 21-22: 10-24 hours

Other outcomes

  1. Tumor Response Assessment for Measurable Lesions According to RECIST, v1.1 (Response Evaluation Criteria in Solid Tumors)

    Positron emission tomography - computed tomography (ET-CT), CT, or magnetic resonance imaging (MRI) scans of all anatomic regions involved with the disease were performed to assess tumor response using the Response Evaluation Criteria in Solid Tumors, Version 1.1. (RECIST v1.1). Bone metastases were assessed by bone scintigraphy (bone scan). Tumor measurements and evaluation of tumor response were performed at baseline and within the last 7 days of Cycle 2. Thereafter, if subjects continued regorafenib treatment, tumor assessments were performed after every third cycle and at the end-of-treatment (EOT) visit. In addition, outcome of "Assessment of Bone Metastases by Scintigraphy if Applicable (Bone Scan)" was registered, the results of which has been reported as tumor response in this outcome as well.

    Time frame: Up to 6 months

07

Results

Posted Feb 20, 2017

Participant flow

Overall, 39 adult male or female participants with locally advanced and / or metastatic solid tumors were screened at 4 study centers in Canada and 4 study centers in the USA.

Participant flow — Overall Study
MilestoneRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment
Started186
Received treatment186
Completed00
Not completed186
Withdrew: Withdrawal by subject11
Withdrew: Adverse event42
Withdrew: Disease progression133

Outcome measures

PrimaryAUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation. The AUC(0-tlast) \[Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point \>LLOQ (Lower Limit of Quantification)\] is a measure of systemic drug exposure from time 0 up to the time point at which the last measurable drug could be detectable, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · mg*h/L
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
mg*h/LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib67.2 ± 45.576.6 ± 50.3
Regorafenib metabolites M-227.8 ± 80.419.0 ± 58.7
Regorafenib metabolites M-55.25 ± 1452.34 ± 79.8
Statistical analysis
  • Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment vs Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment · Ls mean: 1.14 · 90% CI 0.796 to 1.63
  • Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment vs Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment · Ls-means: 0.684 · 90% CI 0.397 to 1.18
  • Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment vs Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment · Ls-means: 0.446 · 90% CI 0.200 to 0.996
PrimaryAE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8

Amount of drug excreted into urine during the collection interval 0-24 hours post dose was expressed as percentage of administered dose.

Time frame:
Days 1-2: 0-24 hours
Reported as:
Mean · percentage of dose
AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8
percentage of doseRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib metabolites M-73.607 ± 1.1241.309 ± 0.649
Regorafenib metabolites M-81.120 ± 0.7370.184 ± 0.229
SecondaryAUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation. AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · mg*h/L
AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
mg*h/LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib (n=6, 3)59.5 ± 26.198.7 ± 71.0
Regorafenib metabolites M-2 (n=13, 4)32.6 ± 89.020.8 ± 65.4
Regorafenib metabolites M-5 (n=0, 0)NA ± NANA ± NA
SecondaryAUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation. The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUC(0-24) is defined as AUC divided from zero to 24 hours after single (first) dose.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10 and 24 hours post-dose
Reported as:
Geometric mean · mg*h/L
AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
mg*h/LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib30.0 ± 39.828.4 ± 62.0
Regorafenib metabolites M-213.5 ± 70.07.93 ± 72.7
Regorafenib metabolites M-51.17 ± 1160.474 ± 101
SecondaryCmax (Maximum Drug Concentration in Plasma After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · mg/L
Cmax (Maximum Drug Concentration in Plasma After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
mg/LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib2.45 ± 472.00 ± 69.7
Regorafenib metabolites M-21.01 ± 66.70.525 ± 69.6
Regorafenib metabolites M-50.0877 ± 1250.0341 ± 67.0
SecondaryTmax (Time to Reach Maximum Drug Concentration in Plasma After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation.Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Median · h
Tmax (Time to Reach Maximum Drug Concentration in Plasma After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
hRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib4.03 (1.00 to 24.0)3.04 (1.00 to 23.75)
Regorafenib metabolites M-24.03 (1.00 to 24.0)6.04 (1.98 to 23.8)
Regorafenib metabolites M-547.8 (6.00 to 96.1)48.9 (24.1 to 95.8)
SecondaryTlast (Time of Last Data Point >LLOQ) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

based on non-compartmental PK evaluation.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Median · h
Tlast (Time of Last Data Point >LLOQ) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
hRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib95.7 (46.4 to 96.3)95.8 (95.6 to 96.0)
Regorafenib metabolites M-295.7 (46.4 to 96.3)95.8 (95.6 to 96.0)
Regorafenib metabolites M-595.7 (46.4 to 96.3)95.8 (95.6 to 96.0)
Secondaryt1/2 (Half-life Associated With the Terminal Slope) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation. t1/2 refers to the elimination of the drug. It is the time taken for the blood plasma concentration to reach half the concentration in the terminal phase of elimination. It is expressed in hours (h) and derived from the terminal slope of the concentration versus time curve.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · h
t1/2 (Half-life Associated With the Terminal Slope) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
hRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib (n=6, 3)28.7 ± 23.027.9 ± 32.0
Regorafenib metabolites M-2 (n=13, 4)26.2 ± 25.725.5 ± 24.0
Regorafenib metabolites M-5 (n=0, 0)NA ± NANA ± NA
SecondaryCL/F (Total Body Clearance of Drug After Extravascular Administration) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation.Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · L/H
CL/F (Total Body Clearance of Drug After Extravascular Administration) After Single (First) Dose for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
L/HRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib (n=6, 3)2.69 ± 26.11.62 ± 71.0
Regorafenib metabolites M-2 (n=13, 4)5.08 ± 89.07.95 ± 65.4
Regorafenib metabolites M-5 (n=0, 0)NA ± NANA ± NA
SecondaryVz/F (Apparent Volume of Distribution During Terminal Phase After Single (First) Oral Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation.Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · L
Vz/F (Apparent Volume of Distribution During Terminal Phase After Single (First) Oral Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib (n=6, 3)111 ± 31.965.2 ± 81.0
Regorafenib metabolites M-2 (n=13, 4)192 ± 83.8292 ± 71.1
Regorafenib metabolites M-5 (n=0, 0)NA ± NANA ± NA
SecondaryAUC(0-24)md ((AUC(0-24) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation.

Time frame:
Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10 and 24 hours post-dose
Reported as:
Geometric mean · mg*h/L
AUC(0-24)md ((AUC(0-24) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
mg*h/LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib56.0 ± 56.445.2 ± 45.8
Regorafenib metabolites M-253.9 ± 63.135.0 ± 207
Regorafenib metabolites M-549.7 ± 13034.2 ± 438
SecondaryCmax,md (Cmax After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

Time frame:
Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · mg/L
Cmax,md (Cmax After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
mg/LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib3.52 ± 54.92.87 ± 62.2
Regorafenib metabolites M-23.52 ± 58.82.29 ± 257
Regorafenib metabolites M-53.25 ± 1332.23 ± 659
SecondaryAUC(0-tlast)md (AUC(0-tlast) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

based on non-compartmental PK evaluation.

Time frame:
Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Geometric mean · mg*h/L
AUC(0-tlast)md (AUC(0-tlast) After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
mg*h/LRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib133 ± 55.1111 ± 54.8
Regorafenib metabolites M-2136 ± 64.992.3 ± 280
Regorafenib metabolites M-5183 ± 128134 ± 459
SecondaryTmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

based on non-compartmental PK evaluation

Time frame:
Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Median · h
Tmax,md (Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
hRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib3.97 (0.000 to 23.8)4.25 (0.000 to 10.0)
Regorafenib metabolites M-24.12 (0.000 to 23.9)4.00 (0.000 to 10.0)
Regorafenib metabolites M-50.000 (0.000 to 24.0)0.000 (0.000 to 8.00)
SecondaryTlast,md (Tlast After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

based on non-compartmental PK evaluation

Time frame:
Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose
Reported as:
Median · h
Tlast,md (Tlast After Multiple-dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
hRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib96.0 (48.1 to 96.5)95.3 (94.3 to 96.0)
Regorafenib metabolites M-296.0 (48.1 to 96.5)95.3 (94.3 to 96.0)
Regorafenib metabolites M-596.0 (48.1 to 96.5)95.3 (94.3 to 96.0)
SecondaryRACmax (Accumulation Ratio Calculated From Cmax,md and Cmax) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation. Accumulation ratio based on maximum plasma concentration (Cmax) was calculated as ratio of Cmax,md and Cmax.

Time frame:
Up to 25 days
Reported as:
Geometric mean · Accumulation Ratio
RACmax (Accumulation Ratio Calculated From Cmax,md and Cmax) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Accumulation RatioRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib1.51 ± 60.01.96 ± 68.2
Regorafenib metabolites M-23.83 ± 44.95.94 ± 216
Regorafenib metabolites M-539.7 ± 94.081.8 ± 515
SecondaryRAAUC (Accumulation Ratio Calculated From AUC(0-24)md and AUC(0-24)) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation. RAAUC calculated as ratio of AUC(0-24)md and AUC(0-24).

Time frame:
Up to 25 days
Reported as:
Geometric mean · Accumulation Ratio
RAAUC (Accumulation Ratio Calculated From AUC(0-24)md and AUC(0-24)) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Accumulation RatioRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib1.97 ± 57.11.96 ± 52.0
Regorafenib metabolites M-24.32 ± 45.06.00 ± 172
Regorafenib metabolites M-548.3 ± 76.087.0 ± 585
SecondaryRLin (Linearity Factor Calculated as Ratio From AUC(0-24)md and AUC) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5

Based on non-compartmental PK evaluation. RLin is the linearity factor of PK after multiple administrations of identical doses calculated as ratio of AUC(0-24)md and AUC.

Time frame:
Up to 25 days
Reported as:
Geometric mean · Linearity factor calculated as ratio
RLin (Linearity Factor Calculated as Ratio From AUC(0-24)md and AUC) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5
Linearity factor calculated as ratioRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib (n=5, 2)0.957 ± 49.20.469 ± 5.24
Regorafenib metabolites M-2 (n= 9, 2)1.98 ± 40.71.19 ± 144
Regorafenib metabolites M-5 (n=0, 0)NA ± NANA ± NA
SecondaryAE,ur(0-24)md (AE,ur(0-24) After Multiple-dose Administration) for Metabolites M-7 and M-8

based on non-compartmental PK evaluation

Time frame:
Days 21-22: 0-24 hours
Reported as:
Mean · percentage of dose
AE,ur(0-24)md (AE,ur(0-24) After Multiple-dose Administration) for Metabolites M-7 and M-8
percentage of doseRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib metabolites M-75.094 ± 2.3221.647 ± 0.753
Regorafenib metabolites M-82.566 ± 1.5611.238 ± 0.684
SecondaryAE,ur(0-10) Stage 1 (Amount of Drug Excreted Via Urine During the Collection Interval 0-10 Hours Post Administration) for Metabolites M-7 and M-8

based on non-compartmental PK evaluation

Time frame:
Days 1-2: 0-10 hours
Reported as:
Mean · percentage of dose
AE,ur(0-10) Stage 1 (Amount of Drug Excreted Via Urine During the Collection Interval 0-10 Hours Post Administration) for Metabolites M-7 and M-8
percentage of doseRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib metabolites M-71.752 ± 0.6110.449 ± 0.301
Regorafenib metabolites M-80.486 ± 0.3820.053 ± 0.089
SecondaryAE,ur(10-24) Stage 1 ((Amount of Drug Excreted Via Urine During the Collection Interval 10-24 Hours Post Administration) for Metabolites M-7 and M-8

based on non-compartmental PK evaluation

Time frame:
Days 1-2: 10-24 hours
Reported as:
Mean · percentage of dose
AE,ur(10-24) Stage 1 ((Amount of Drug Excreted Via Urine During the Collection Interval 10-24 Hours Post Administration) for Metabolites M-7 and M-8
percentage of doseRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib metabolites M-71.855 ± 0.6290.746 ± 0.441
Regorafenib metabolites M-80.634 ± 0.3740.117 ± 0.133
SecondaryAE,ur(0-10) Stage 2 for Metabolites M-7 and M-8

based on non-compartmental PK evaluation

Time frame:
Days 21-22: 0-10 hours
Reported as:
Mean · percentage of dose
AE,ur(0-10) Stage 2 for Metabolites M-7 and M-8
percentage of doseRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib metabolites M-72.655 ± 1.3460.600 ± 0.255
Regorafenib metabolites M-81.292 ± 0.9020.469 ± 0.338
SecondaryAE,ur(10-24) Stage 2 for Metabolites M-7 and M-8

based on non-compartmental PK evaluation

Time frame:
Days 21-22: 10-24 hours
Reported as:
Mean · percentage of dose
AE,ur(10-24) Stage 2 for Metabolites M-7 and M-8
percentage of doseRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Regorafenib metabolites M-72.440 ± 1.0981.047 ± 0.738
Regorafenib metabolites M-81.274 ± 0.7120.769 ± 0.497
Other pre-specifiedTumor Response Assessment for Measurable Lesions According to RECIST, v1.1 (Response Evaluation Criteria in Solid Tumors)

Positron emission tomography - computed tomography (ET-CT), CT, or magnetic resonance imaging (MRI) scans of all anatomic regions involved with the disease were performed to assess tumor response using the Response Evaluation Criteria in Solid Tumors, Version 1.1. (RECIST v1.1). Bone metastases were assessed by bone scintigraphy (bone scan). Tumor measurements and evaluation of tumor response were performed at baseline and within the last 7 days of Cycle 2. Thereafter, if subjects continued regorafenib treatment, tumor assessments were performed after every third cycle and at the end-of-treatment (EOT) visit. In addition, outcome of "Assessment of Bone Metastases by Scintigraphy if Applicable (Bone Scan)" was registered, the results of which has been reported as tumor response in this outcome as well.

Time frame:
Up to 6 months
Reported as:
Number · participants
Tumor Response Assessment for Measurable Lesions According to RECIST, v1.1 (Response Evaluation Criteria in Solid Tumors)
participantsRegorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Complete response (CR)00
Partial response (PR)00
Stable disease (SD)105
Non CR/Non PD00
Progressive disease (PD)51
Not evaluable00

Adverse events

Collected over From start of study treatment until 30 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Impairment—9/18 (50%)18/18 (100%)
Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment—2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventRegorafenib(Stivarga, BAY73-4506)-Normal/Mild ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
Chest painGeneral disorders0/181/6
Muscular weaknessMusculoskeletal and connective tissue disorders1/181/6
Small intestinal obstructionGastrointestinal disorders2/180/6
Stress cardiomyopathyCardiac disorders1/180/6
Intestinal obstructionGastrointestinal disorders1/180/6
PancreatitisGastrointestinal disorders1/180/6
DehydrationMetabolism and nutrition disorders1/180/6
HaematuriaRenal and urinary disorders1/180/6
Pleural effusionRespiratory, thoracic and mediastinal disorders1/180/6
RashSkin and subcutaneous tissue disorders1/180/6
Most frequent other events
Showing 10 of 153
Most frequent other events
EventRegorafenib(Stivarga, BAY73-4506)-Normal/Mild ImpairmentRegorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment
NauseaGastrointestinal disorders10/186/6
FatigueGeneral disorders13/183/6
DiarrhoeaGastrointestinal disorders8/184/6
VomitingGastrointestinal disorders6/184/6
HypertensionVascular disorders8/184/6
Decreased appetiteMetabolism and nutrition disorders11/183/6
HeadacheNervous system disorders10/182/6
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders10/183/6
Abdominal painGastrointestinal disorders5/183/6
CheilitisGastrointestinal disorders1/183/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib (Stivarga, BAY73-4506)-Severe Renal ImpairmentTotal
Mean62.0 ± 9.664.2 ± 6.962.5 ± 8.9
Gender
Gender(Participants)Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal ImpairmentRegorafenib (Stivarga, BAY73-4506)-Severe Renal ImpairmentTotal
Female9413
Male9211
08

Study locations

9 sites
  • Los Angeles, California 90033, United States
  • Aurora, Colorado 80045, United States
  • St. Louis, Missouri 63110, United States
  • Lebanon, New Hampshire 03756, United States
  • Buffalo, New York 14263-0001, United States
  • Edmonton, Alberta T6G 1Z2, Canada
  • Vancouver, British Columbia V5Z 4E6, Canada
  • Hamilton, Ontario L8V 5C2, Canada
  • Montreal, Quebec H2L 4M1, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jul 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2013
First posted
May 14, 2013
Start
Jun 2013
Primary completionActual
Jul 2015
CompletionActual
Nov 2015
Results first posted
Feb 20, 2017
Last update
Feb 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01853046
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 14, 2013
Start date
Jun 2013
Primary completion
Jul 2015
Completion
Nov 2015
Results posted
Feb 20, 2017
Last update
Feb 20, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion